Toll Reports Better-than-Expected Earnings: Ahead of the Ticker

NEW YORK ( TheStreet) -- Luxury homebuilder Toll Brothers ( TOL) reported better-than-expected second-quarter earnings on increased demand for new homes.

The company reported net income of $24.7 million, or 14 cents a share, up from $16.9 million, or 10 cents a share, in the same quarter last year.

Revenue climbed 38% to $516 million.

Analysts expected earnings of 7 cents a share on $515.5 million in revenue.

"Buyers who have been on the sidelines for six years are jumping in," CEO Douglas Yearley said. "Low interest rates, improved customer confidence, a strong stock market, rising home prices and a reawakening economy are stoking the demand that is fueling our luxury market."

According to Toll, the builder experienced the highest level of quarterly orders in seven years. Its average selling price increased 3.6% in the second quarter to $577,000 per home from a year earlier.

Toll signed contracts for 1,753 homes at a value of $1.19 billion, also the highest figures it's experienced sine 2006. The company signed contracts for 1,290 homes at $754.7 million in the same quarter last year.


Target ( TGT) reported disappointing first-quarter sales, prompting the retailer to issue a lower full-year profit outlook than it previously forecast.

First-quarter sales in the U.S. fell 0.6%, worse than the 0.03% decline analysts predicted, according to Thomson Reuters.

Target earned $498 million, or 77 cents a share, in the quarter ended May 4, down from its profit of $697 million, or $1.04 a share, in the same quarter last year.

Target attributed the weak results to the cooler-than-usual spring weather that weighed on shoppers' seasonal spending.

The company now expects adjusted earnings of $4.70 to $4.90 a share for the full year, below the prior forecast of $4.85 to $5.05 that it issued in April.

Analysts had expected earnings of $4.48 a share for the full year.


Drugmaker GlaxoSmithKline ( GSK) has received a development deal worth up to $200 million from the U.S. government to create new antibiotics.

Per the deal, a first of its kind collaboration between the U.S. government and a drug company, GlaxoSmithKline will focus on developing several drugs that will combat antibiotic resistance and bioterrorism.

The U.S. Department of Health and Human Services will provide $40 million for the first 18 months of the agreement and up to a total of $200 million if the agreement is renewed over a five-year period.


The chatter on Main Street (a.k.a. Google, Yahoo! and other search sites) is always of interest to investors on Wall Street. Thus, each day, TheStreet compiles the stories that are trending on the Web, and highlights the news that could make stocks move.

-- Written by Brittany Umar.

Brittany joined TheStreet.com TV in November 2006 after completing a degree in Journalism and Media Studies at Rutgers College. Previously, Brittany interned at the local ABC affiliate in New York City WABC-TV 7 where she helped research and produce On Your Side, a popular consumer advocacy segment.

More from Stocks

Danica Patrick's Final Race at 2018 Indianapolis 500: What She Thinks About Cars

Danica Patrick's Final Race at 2018 Indianapolis 500: What She Thinks About Cars

Why The FANG Stocks' Dominance May Not Be So Bad For The Market

Why The FANG Stocks' Dominance May Not Be So Bad For The Market

At End of May, Investors Signalling They May Stay Away

At End of May, Investors Signalling They May Stay Away

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Neel Kashkari: The Heart of Our Financial System Is More Radioactive Than Ever

Neel Kashkari: The Heart of Our Financial System Is More Radioactive Than Ever